UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

June 1, 2006

(Date of report)

 

CARACO PHARMACEUTICAL LABORATORIES, LTD.

(Exact name of registrant as specified in its charter)

 

 

Michigan

 

0-24676

 

38-2505723

(State or other jurisdiction
of incorporation)

 

(Commission file number)

 

(I.R.S. employer
identification no.)

 

 

1150 Elijah McCoy Drive, Detroit, Michigan 48202

(Address of principal executive offices)

 

(313) 871-8400

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)

 

o 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 2.02. Results of Operations and Financial Condition

 

On June 5, 2006, registrant announced its results of operations for the year and fourth quarter ended March 31, 2006, as set forth in the press release included as Exhibit 99.1 hereto, which is incorporated herein by reference.

 

Item 3.02. Unregistered Sales of Equity Securities

 

As of June 1, 2006, registrant issued 544,000 shares of Series B Preferred Stock to Sun Pharma Global, Inc. (“Sun Global”) for the transfer of one product pursuant to registrant’s products agreement with Sun Global dated November 21, 2002.

 

The Series B Preferred Stock is convertible into common stock on a one-for one basis after three years from the date of issuance or following a person (other than Sun Pharmaceutical Industries Limited and its affiliates) acquiring control of registrant.

 

The Series B Preferred Stock and the underlying common stock were issued pursuant to exemptions from registration under Section 4(2) under the Securities Act of 1933.

 

Item 9.01. Financial Statements and Exhibits

 

c)

Exhibits.

 

Exhibit No.

Description

 

99.1      Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated June 5, 2006 announcing its results of operations for the year and fourth quarter ended March 31, 2006.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

CARACO PHARMACEUTICAL LABORATORIES, LTD.

 

Date:

June 6, 2006

By:

/s/ Daniel H. Movens

 

 

 

 Daniel H. Movens
 Chief Executive Officer

 

 

2

 

Exhibit Index

 

 

  99.1   Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated June 5, 2006, announcing its results of operations for the year and fourth quarter ended March 31, 2006.

 

3